Treatment of Seronegative Autoimmune Autonomic Ganglionopathy
For seronegative autoimmune autonomic neuropathy (SAAN), initiate treatment with high-dose intravenous corticosteroids as first-line therapy, as this population responds preferentially to steroids rather than antibody-targeted immunotherapies like plasma exchange or IVIG. 1
Key Distinction: Seronegative vs Seropositive Disease
The treatment approach for seronegative disease fundamentally differs from seropositive AAG. This is a critical clinical distinction that directly impacts therapeutic decisions:
- Seronegative patients show predominant sympathetic (rather than cholinergic) failure and respond best to corticosteroids 1
- Seropositive AAG responds to antibody-targeted therapies (plasma exchange, IVIG) 1, 2
- Seronegative patients typically have prominent sensory symptoms and pain, which is less common in seropositive disease 1
First-Line Treatment Algorithm
Initial Therapy
Start with intravenous methylprednisolone as the primary treatment 3, 1. The evidence shows:
- Three out of six seronegative patients in the defining study responded to IV steroids 1
- A case report demonstrated successful treatment with IV methylprednisolone combined with apheresis after 10 months of symptoms 3
- Plasma exchange and IVIG were ineffective in the seronegative cohort 1
If Severe Dysautonomia Present
When patients present with severe dysautonomia, consider combined first-line therapies from the beginning rather than sequential treatment 4. This approach is supported by autoimmune encephalitis guidelines that specifically mention severe dysautonomia as an indication for upfront combination therapy 4.
Specific combination options:
- Corticosteroids + plasma exchange (PLEX) - preferred if severe hyponatremia or high thromboembolic risk present 4
- Corticosteroids + IVIG - preferred in agitated patients or those with bleeding disorders 4
Common Pitfall: Antibody-Targeted Therapy Failure
Critical caveat: Do not persist with plasma exchange or IVIG monotherapy in seronegative patients. The literature consistently shows these modalities are ineffective when used alone in seronegative disease 1. This represents a fundamental difference from seropositive AAG, where antibody removal strategies are cornerstone treatments 5, 2.
Second-Line Options
Rituximab Consideration
If steroids fail or provide insufficient benefit, rituximab can be considered, though evidence is mixed in seronegative disease:
- Only 2 out of 4 seronegative patients responded to rituximab in a systematic review 6
- Rituximab showed better efficacy in seropositive AAG (5/5 cases) 6
- The mechanism may be less effective in seronegative disease since rituximab primarily targets B-cell mediated antibody production 4
Combined Immunosuppression
For refractory cases, consider prednisone plus mycophenolate mofetil followed by plasma exchange cycles, though this evidence comes primarily from seropositive patients 5. The rationale is that prolonged immunosuppression may be necessary even in seronegative disease when initial therapies fail.
Treatment Sequencing
- Start: High-dose IV methylprednisolone
- If no response by 2-4 weeks: Add plasma exchange (5-10 sessions every other day) 4
- If combined first-line therapy fails: Consider rituximab, though response rates are lower in seronegative patients 6
- Maintenance: Gradual oral prednisone taper 4
Monitoring Response
Unlike seropositive AAG where antibody titers guide treatment 2, seronegative patients require clinical monitoring focused on:
- Orthostatic blood pressure measurements
- Gastrointestinal symptom improvement
- Sensory symptom and pain reduction
- Autonomic function testing (cardiovascular autonomic markers, pupillary responses)
Volume Shift Caution
Important warning: Plasma exchange can cause problematic volume shifts in dysautonomic patients 4. When using PLEX in patients with severe orthostatic hypotension, careful fluid management is essential to avoid exacerbating hemodynamic instability.